Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may have improved outcomes when a tyrosine kinase inhibitor is added to chemotherapy (Abstract S117).
Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes compared with intensive chemotherapy in older patients with acute myeloid leukemia, with benefits most pronounced in people at high risk of treatment-related mortality (Abstract S141).
John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerability of acalabrutinib in treatment-naive patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract S163).
Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphamide, vincristine, and prednisolone is a feasible and effective regimen for front-line treatment of high-risk patients with diffuse large B-cell lymphoma who are not eligible for standard chemotherapy (Abstract S232).
Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide a refined understanding of the ponatinib benefit/risk profile and its relation to dose. Mature data from continued follow-up may support an alternate dosing regimen for patients with chronic phase chronic myeloid leukemia (Abstract S172).
Michael J. Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Centre, discusses phase I dose-escalation study results on CD20-TCB, which showed activity, including durable complete responses, and manageable safety in heavily pretreated patients with relapsed or refractory non-Hodgkin lymphoma (Abstract S241).
